Menta Capital LLC grew its position in shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 9.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 431,996 shares of the specialty pharmaceutical company’s stock after acquiring an additional 35,660 shares during the period. SciClone Pharmaceuticals comprises 0.6% of Menta Capital LLC’s portfolio, making the stock its 5th largest position. Menta Capital LLC owned 0.84% of SciClone Pharmaceuticals worth $4,752,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of SCLN. Teachers Advisors LLC raised its stake in shares of SciClone Pharmaceuticals by 3.0% during the fourth quarter. Teachers Advisors LLC now owns 80,483 shares of the specialty pharmaceutical company’s stock valued at $869,000 after acquiring an additional 2,370 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of SciClone Pharmaceuticals by 2.4% during the first quarter. Louisiana State Employees Retirement System now owns 21,000 shares of the specialty pharmaceutical company’s stock valued at $206,000 after acquiring an additional 500 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of SciClone Pharmaceuticals by 23.9% during the first quarter. Russell Investments Group Ltd. now owns 162,121 shares of the specialty pharmaceutical company’s stock valued at $1,589,000 after acquiring an additional 31,254 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of SciClone Pharmaceuticals by 24.8% during the first quarter. Wells Fargo & Company MN now owns 181,492 shares of the specialty pharmaceutical company’s stock valued at $1,779,000 after acquiring an additional 36,034 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in shares of SciClone Pharmaceuticals by 5.5% during the first quarter. Great West Life Assurance Co. Can now owns 71,971 shares of the specialty pharmaceutical company’s stock valued at $702,000 after acquiring an additional 3,739 shares during the last quarter. 72.86% of the stock is owned by hedge funds and other institutional investors.

Separately, Maxim Group reaffirmed a “hold” rating on shares of SciClone Pharmaceuticals in a research note on Thursday, June 8th.

In other SciClone Pharmaceuticals news, CEO Hong Zhao sold 30,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $330,000.00. Following the completion of the sale, the chief executive officer now directly owns 30,000 shares of the company’s stock, valued at approximately $330,000. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Lan Xie sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total transaction of $110,000.00. Following the completion of the sale, the vice president now directly owns 10,000 shares of the company’s stock, valued at $110,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 75,044 shares of company stock valued at $825,484. 5.16% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “SciClone Pharmaceuticals, Inc. (SCLN) Stake Boosted by Menta Capital LLC” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/19/sciclone-pharmaceuticals-inc-scln-stake-boosted-by-menta-capital-llc.html.

Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) remained flat at $11.10 during trading on Tuesday. 68,818 shares of the stock traded hands. SciClone Pharmaceuticals, Inc. has a 12 month low of $8.55 and a 12 month high of $11.43. The company has a 50 day moving average price of $11.05 and a 200-day moving average price of $10.35. The company has a market cap of $579.32 million, a PE ratio of 13.69 and a beta of 1.76.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.10%. The firm had revenue of $44.52 million during the quarter. On average, equities analysts forecast that SciClone Pharmaceuticals, Inc. will post $0.94 EPS for the current fiscal year.

SciClone Pharmaceuticals Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.